4//SEC Filing
KalVista Pharmaceuticals, Inc. 4
Accession 0001140361-16-087737
$KALVCIK 0001348911operating
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 1:35 PM ET
Size
10.4 KB
Accession
0001140361-16-087737
Insider Transaction Report
Form 4
Renzi David
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2016-11-21$7.84/sh+36,640$287,258→ 36,640 total - Tax Payment
Common Stock
2016-11-21$8.59/sh−33,454$287,477→ 3,186 total - Disposition from Tender
Common Stock
2016-11-21$8.59/sh−3,186$27,378→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2016-11-21−36,640→ 0 totalExercise: $7.84Exp: 2023-06-06→ Common Stock (36,640 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction.
- [F2]The option is fully vested and exercisable.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001348911
Filing Metadata
- Form type
- 4
- Filed
- Nov 22, 7:00 PM ET
- Accepted
- Nov 23, 1:35 PM ET
- Size
- 10.4 KB